Athenex Inc
Most Recent
A Focus on Pipeline Expansion Bodes Well for Athenex
Athenex announced a strategic investment of $100 million from Perceptive Advisors.
How Athenex’s Business Segments Performed in Q1 2018
Athenex (ATNX) operates in three business segments—Oncology Innovative Platform, Global Supply Chain Platform, and Commercial Platform.
Understanding Athenex’s Research Platforms
Athenex’s (ATNX) Orascovery platform is based on the P-gp pump inhibitor molecule, HM30181A. Athenex licensed the molecule from Hanmi.
Analysts’ Ratings for Athenex and Its Peers in March
Of the six analysts covering Athenex in March 2018, five analysts gave the stock a “buy” rating, while one analyst gave it a “hold” rating.